CA2143070C - Formulation pharmaceutique sous forme de suspension liquide administree par voie orale, pour degagement prolonge - Google Patents

Formulation pharmaceutique sous forme de suspension liquide administree par voie orale, pour degagement prolonge Download PDF

Info

Publication number
CA2143070C
CA2143070C CA 2143070 CA2143070A CA2143070C CA 2143070 C CA2143070 C CA 2143070C CA 2143070 CA2143070 CA 2143070 CA 2143070 A CA2143070 A CA 2143070A CA 2143070 C CA2143070 C CA 2143070C
Authority
CA
Canada
Prior art keywords
cellulose
oil
water
polysucrose
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA 2143070
Other languages
English (en)
Other versions
CA2143070A1 (fr
Inventor
Pankaj Modi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generex Pharmaceuticals Inc
Original Assignee
Generex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharmaceuticals Inc filed Critical Generex Pharmaceuticals Inc
Publication of CA2143070A1 publication Critical patent/CA2143070A1/fr
Application granted granted Critical
Publication of CA2143070C publication Critical patent/CA2143070C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

CA 2143070 1994-02-22 1995-02-21 Formulation pharmaceutique sous forme de suspension liquide administree par voie orale, pour degagement prolonge Expired - Lifetime CA2143070C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19993394A 1994-02-22 1994-02-22
US08/199,933 1994-02-22

Publications (2)

Publication Number Publication Date
CA2143070A1 CA2143070A1 (fr) 1995-08-23
CA2143070C true CA2143070C (fr) 2001-12-18

Family

ID=22739620

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2143070 Expired - Lifetime CA2143070C (fr) 1994-02-22 1995-02-21 Formulation pharmaceutique sous forme de suspension liquide administree par voie orale, pour degagement prolonge

Country Status (1)

Country Link
CA (1) CA2143070C (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103622942A (zh) * 2013-11-04 2014-03-12 江苏大学 左旋多巴/卡比多巴复方缓释混悬剂及其制备方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
DK0994872T3 (da) * 1997-06-10 2001-05-28 Synthon Bv 4-phenylpiperidin-forbindelser
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
BR9914418A (pt) * 1998-10-13 2001-06-26 Pfizer Prod Inc Concentrado oral de sertralina
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
PT3192500T (pt) * 2009-05-19 2021-01-05 Neuroderm Ltd Composições para a administração contínua de inibidores da dopa decarboxilase
ES2967693T3 (es) 2014-03-13 2024-05-03 Neuroderm Ltd Composiciones del inhibidor de la dopa descarboxilasa
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
AU2016258179B2 (en) * 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103622942A (zh) * 2013-11-04 2014-03-12 江苏大学 左旋多巴/卡比多巴复方缓释混悬剂及其制备方法

Also Published As

Publication number Publication date
CA2143070A1 (fr) 1995-08-23

Similar Documents

Publication Publication Date Title
CA2143070C (fr) Formulation pharmaceutique sous forme de suspension liquide administree par voie orale, pour degagement prolonge
AU2001255680B2 (en) Guaifenesin sustained release formulation and tablets
CA1318602C (fr) Combinaison carbidopa/levodopa a liberation controlee
JP5775464B2 (ja) 非晶質ｃｄｄｏ−ｍｅを含有する遅延放出性経口投薬組成物
MXPA06011860A (es) Composiciones farmaceuticas que comprende un almidon anfifilico.
JPH09503495A (ja) 高濃度アセトアミノフェン溶液含有ゼラチンカプセル
WO1994025008A1 (fr) Compositions pharmaceutiques contenant de la polyvinylpyrrolidone et un tri-ester, et procede pour leur formation
FI87528B (fi) Foerfarande foer framstaellning av en oral dosenhet av kaliumklorid
TW201114766A (en) Pharmaceutical composition for a hepatitis C viral protease inhibitor
AU2011207061B2 (en) Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
CZ20012661A3 (cs) Matricová tableta pro prodlouľené uvolňování gliclazidu po orálním podání
KR20070113289A (ko) 멘톨 또는 ｐｅｇ/폴록사머를 함유하는 개선된페노피브레이트 제제
EP0152292A2 (fr) Gélules contenant de l'acétaminophène
RU2493843C2 (ru) Содержащие ацеклофенак пероральные лекарственные средства с контролируемым высвобождением и способ их изготовления
WO2003013481A1 (fr) Procede de production de composition pharmaceutique a teneur accrue en ingredients pharmaceutiques peu solubles
CZ20031020A3 (en) Compositions comprising modafinil compounds
JP4394447B2 (ja) アセトアミノフェン組成物
CN101632661A (zh) 复方阿莫西林缓释干混悬及其制备
JP6990470B2 (ja) レナリドミド胃内滞留型徐放錠及びその調製方法
WO2016084099A1 (fr) Composition de capsule en gélatine souple d'agents antitussifs
WO2009009737A1 (fr) Formulation à libération prolongée de produits pharmaceutiques actifs pour une libération prolongée à base de lipides
CN1895230A (zh) 赖诺普利滴丸及其制备方法
RU2788873C2 (ru) Фармацевтическая лекарственная форма для эмульсии симетикона и лоперамида
JP6641626B2 (ja) 制酸用医薬組成物
FR2560047A1 (fr) Compositions de bromocriptine

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20150223